ALNY

143.8202.71%
JV

Jeffrey V. Poulton

CFO & Executive VP

Mr. Jeffrey V. Poulton, also Known as Jeff, MBA, has been Executive Vice President and Chief Financial Officer at Alnylam Pharmaceuticals, Inc. since August 13, 2019. He serves as an Independent Director of CervoMed Inc. (Formerly, EIP Pharma, Inc.) since August 2023. Mr. Poulton was the Chief Financial Officer of Shire plc since April 29, 2015 until December 31, 2017 and served as its Interim Chief Financial Officer from January 1, 2015 to April 2015 and served as its Head of Investor Relations since June 2014 until December 2014 and Senior Vice President and brought to his role his financial, commercial and strategic acumen. Prior to his role at Alnylam, Mr. Poulton served as CFO at Indigo Agriculture, from January 2018 to April 2019, where he supported the initial commercial scale-up of the business, including expansion outside the US. Mr. Poulton joined Shire in 2003 and held leadership positions in finance supporting the neuroscience, gastrointestinal and rare disease business units until December 2017. He oversaw the rare diseases business unit operations in North America, Latin America and Asia Pacific and led the integration of Viropharma's rare disease products into the Shire portfolio. He has been a Director of Homology Medicines, Inc. since July 21, 2020 and has been its Lead Independent Director since September 2022. He served at Cinergy Corp. and PPG Industries in a variety of corporate finance and business development roles. He had been Director of Shire plc since April 29, 2015 until December 31, 2017. He served for four years in the U.S. Navy as a Commissioned Officer. He has a Bachelor of Arts in Economics from Duke University and a Master of Business Administration in Finance from the Kelly School of Business at Indiana University.

Positions